How Pharma Authentication Tech Enhances ROI and Safety

How Pharma Authentication Tech Enhances ROI and Safety

Ankit Gupta, President, ASPA

 Ankit Gupta, President, ASPA

In an exclusive interview with Thiruamuthan, Assistant Editor at India Pharma Outlook, Ankit Gupta, President of ASPA, discusses how serialization and digital authentication are driving a paradigm shift in the pharmaceutical industry. He highlights that companies are increasingly adopting these technologies to combat counterfeiting, enhance supply chain transparency, and recover revenue lost to fake products. The approach integrates physical security elements such as holograms with digital tools like QR codes and blockchain for end-to-end traceability. Driven by regulatory mandates and growing consumer awareness, brands now recognize these investments as strategic enablers of long-term value rather than operational expenses.  

With counterfeit drugs still affecting India’s pharmaceutical industry, how are companies adopting serialization and digital authentication technologies to ensure integrity and measurable ROI? 

In various industries, particularly within the pharmaceutical sector, companies are increasingly implementing serialization and digital authentication technologies to safeguard product integrity and achieve measurable returns on investment (ROI). From an industry standpoint, understanding how a product moves through the supply chain is no longer optional, it is essential to ensuring authenticity, safety, and regulatory compliance. 

At the core of combatting counterfeiting lie two essential components. First, there must be a physical security element applied directly to the product or its packaging, enabling consumer-level authentication. This includes technologies such as holography, variable data printing, security printing, and specialized inks. More advanced innovations like micro-optics and RFID are also being explored for broader implementation. These physical layers provide a first line of defense by enabling consumers, retailers, or auditors to verify the authenticity of a product at the point of sale or use. 

Second, there is a digital traceability layer that ensures complete visibility and transparency across the entire supply chain, from manufacturing through distribution to retail. Technologies like QR codes and RFID (in future applications) allow for real-time tracking of every SKU (stock-keeping unit). As products move through various stages of the supply chain, their data is captured and made accessible, ensuring full traceability, accountability, and tamper detection. 

From a financial and operational standpoint, the ROI of such anti-counterfeiting measures is compelling. For instance, consider a company with a 100 crore annual turnover facing a 20% counterfeit impact; this equates to a 20 crore loss in revenue. With a 10% profit margin, that translates into a direct 2 crore loss in profit. Transitioning from traditional packaging to smart, secure packaging solutions may cost between 10 lakh and 50 lakh. Even at the higher end of the investment, the return can be 400% or more, solely based on recovered profit, excluding the additional value of enhanced brand reputation and customer trust. 

Moreover, anti-counterfeiting solutions should be viewed as strategic investments, not as operational expenses. Beyond profit recovery, these solutions reflect a brand’s commitment to quality, consumer safety, and market credibility key pillars in maintaining and growing brand goodwill in competitive markets. 

The urgency for adoption is further underscored by recent incidents. In one case, counterfeit pharmaceutical products reportedly entered the supply chain, resulting in confusion at the retail level. A chemist or distributor allegedly ended up selling unauthorized or incorrect products. Whether due to deliberate malpractice or infiltration by counterfeiters, the incident highlights the critical need for end-to-end authentication and traceability systems. Notably, such systems not only prevent related issues but also provide the audit trail needed for accountability and corrective action. 

As industry challenges evolve, it is imperative for manufacturers, brand owners, and supply chain stakeholders to view product authentication and serialization not just as safeguards, but as enablers of trust, efficiency, and long-term value creation. 

Also Read: India's Path to Billion-Dollar Drugs: Building a Strong Ecosystem

Despite growing adoption of authentication systems, operational and regulatory hurdles persist, how are manufacturers overcoming these to integrate technology efficiently across supply chains? 

As part of the evolving journey in combating counterfeiting, brands were initially hesitant to acknowledge the existence of this issue in the market. Many were reluctant to admit, especially in public forums or marketplaces that counterfeit versions of their products existed, largely due to concerns about damaging consumer trust. 

However, this mindset has shifted significantly over the past four to five years. Brands are now increasingly open about recognizing counterfeiting as a real and pressing problem. There has been a clear and encouraging trend of companies becoming more comfortable with acknowledging the issue and actively seeking solutions. 

A notable example of this change is Mankind Pharma, which recently took a strong and commendable step by openly discussing the technologies being implemented within their supply chain. Their focus has been on both product authentication and preventing counterfeit items from entering the distribution network. 

As block chain and track-and-trace solutions gain traction, how are manufacturers implementing real-time serialization and digital tagging to secure drug integrity across India’s fragmented distribution networks? 

Supply chain solutions are evolving from relying on a single technology to leveraging a combination of technologies. As the shift occurs from purely physical solutions to digital ones, digital traceability becomes a key component. On one side, digital traceability requires a physical carrier on the product, such as a QR code or RFID tag. On the other side, it requires software to track and trace the product throughout the supply chain. This software could be built on traditional technologies like .NET or Java, or it could utilize block chain to enable traceability even at the pre-supply chain level. 

As a result, an interesting and diverse bouquet of solutions is emerging, combining both traditional and new technologies across physical and digital domains. These integrated approaches are now enabling comprehensive traceability solutions across the entire supply chain. Such a solution can potentially serve two different purposes for a brand. First, it can be used internally, allowing audit teams to track and trace the supply chain to ensure that only authentic products are being distributed in the market. Second, the brand can empower consumers directly through an app or similar interface, enabling them to verify product authenticity before making a purchase. 

Furthermore, leading brands both globally and within India are beginning to adopt these digital traceability solutions, reflecting a growing awareness of the value of transparency, authenticity, and consumer trust in the modern supply chain.

Serialization and digital authentication have moved beyond compliance—they’re now strategic levers driving trust, transparency, and tangible ROI across a pharmaceutical industry battling counterfeit challenges

 

While companies invest heavily in authentication solutions, how are they quantifying ROI through reduced counterfeiting incidents, improved recall efficiency, and measurable operational gains? 

From an industry standpoint, the conversation around ROI is increasingly grounded in a clear, well-defined use case for adopting traceability and authenticity solutions. A fundamental shift that needs to take place within enterprises is the realization that such initiatives are not operational expenses, but strategic investments. When organizations begin to view the money spent on these technologies as a direct contributor to their bottom line, the mindset changes.  

This investment recovers revenue that rightfully belongs to the brand but is currently lost to counterfeiting and supply chain inefficiencies. In addition to enhancing profitability, these solutions protect brand equity and consumer trust, both of which are vital assets in competitive markets. 

Moreover, the rationale extends beyond financial gains. There is a strong socio-economic case for industry-wide adoption. First, it delivers measurable ROI through higher revenues and operational transparency. Second, it strengthens brand reputation and consumer loyalty by ensuring that only genuine, high-quality products reach the market. Third, it promotes ethical manufacturing practices by ensuring that production takes place in compliant facilities that uphold labor laws and fair wages.  

For the industry, investing in digital traceability and authentication technologies is not just a business decision it is a contribution to India’s broader development goals. This aligns with the national vision of Viksit Bharat, where innovation, compliance, and ethical practices form the backbone of industrial progress. The responsibility to build a trusted and transparent ecosystem does not rest with the government alone. 

Every industry player be it manufacturers, suppliers, or brand owners must play an active role in shaping a future where Indian industry is globally competitive, consumer-centric, and aligned with the values of integrity and inclusivity. 

Also Read: Anti-Infectives: How New Research is Shaping Infection Control

Given increasing regulatory pressure and consumer awareness, what are the key drivers influencing Indian pharma companies’ investments in advanced authentication technologies? 

At a fundamental level, from a regulatory perspective, there is a growing recognition by the government that counterfeiting and supply chain integrity is genuine and pressing issues. The government clearly understands the seriousness of the problem and acknowledges that, as a nation, India must focus on "Make in India".  

 Furthermore, to build and maintain goodwill on a national level, it is imperative that every company ensures the integrity of its supply chain. One of the key regulatory initiatives currently underway is focused on the top 300 Active Pharmaceutical Ingredients (APIs). For the first time, any pharmaceutical product being exported from India is expected to incorporate QR codes as part of its traceability mechanism. This marks an important first step by the government toward ensuring supply chain transparency in the pharmaceutical sector

However, while this initiative is commendable, it is not yet a complete solution. There is always room for improvement, and the government can certainly do more to strengthen these efforts. Any single technology, while useful, comes with its own limitations. 

 Therefore, a multi-technology approach is essential to build a solution that is not only traceable but also secure. The expectation is that such comprehensive solutions will evolve over time. The industry is encouraged by the direction the government has taken and remains optimistic that more robust, scalable, and integrated frameworks will be developed to address the complexities of supply chain integrity and product authentication on a national and global scale

With AI, IoT, and next-gen digital authentication emerging rapidly, how will these technologies transform pharmaceutical security and ROI in India over the next five years? 

The evolution of the authentication and traceability industry is unfolding naturally. Looking at the journey of the Authentication Solution Providers' Association (ASPA), the transformation is clear. Initially known as HOMAI (Hologram Manufacturers Association of India), the organization began with a focus on a single technology. Over time, ASPA recognized that multiple technologies were addressing the same core problem, counterfeiting and supply chain integrity, and thus expanded its scope to include a broader range of solutions. Several physical authentication technologies were integrated first, followed more recently by the inclusion of traceability technologies, which are now a critical part of the industry’s offerings. 

ASPA now hosts a flagship event called the Traceability and Authentication Forum (TASK), held approximately every 18 months. This platform brings together stakeholders from across the ecosystem, regulators, brand owners, and providers of various authentication technologies to collaborate on identifying viable, long-term solutions. It has become a significant gathering to shape the future of the industry. 

In terms of emerging technologies like blockchain, AI, and IoT, the industry views their adoption as part of a clear and ongoing journey. Notably, each technology addresses different aspects of the problem, and when integrated, they form a comprehensive solution. For example, one technology may secure the physical aspects of a product, while another ensures digital traceability, and together they cover the full spectrum of risks. The role of authentication solution providers is to seamlessly combine these technologies to build robust systems for brands. 

The industry often draws a parallel with the ongoing battle between viruses and antivirus software. Just as viruses evolve, prompting the development of stronger antiviruses, counterfeiters continually refine their tactics. The authentication industry must constantly innovate and improve to stay ahead, developing more secure, transparent, and advanced solutions for today’s and tomorrow’s challenges. 

Addressing recent incidents such as the cough syrup contamination cases, the industry strongly believes that stronger authentication and traceability systems could have significantly mitigated such failures. These incidents are deeply unfortunate and unacceptable, especially when children's lives are impacted. Although the specifics of the brand involved in that case may not be widely known, it is evident that the necessary technologies are already available in the market. 

From a technical standpoint, companies could have implemented physical authentication through security labels or moved to track-and-trace systems. The adoption of serialization and real-time verification tools would have ensured transparency and accountability across the supply chain. However, the implementation depends heavily on the intent and commitment of the brand owners. The industry maintains that this should not be seen as an expense, but as a critical investment in quality and consumer safety. 

Currently, the authentication and traceability sector is witnessing unprecedented growth, precisely because more brands are recognizing the importance of these solutions. While there is always room for improvement, both from the industry's side and the government's efforts are actively being made. ASPA continues to play a key role in advocating policy and regulatory changes, engaging with the government and stakeholders to emphasize the urgency of the problem. 

The association firmly believes that if a consumer is paying for a product, they have the right to receive a genuine and safe product. Incidents like the contaminated cough syrup serve as a wake-up call. The mandatory adoption of serialization and authentication technologies, especially in pharmaceuticals, should be a national priority.  

 

on the deck

Most Viewed

Addressing Antimicrobial Resistance (AMR) Through Collaborative Efforts Fostering a Quality Culture in the Pharmaceutical Industry Advancements in Computer-Aided Drug Design for Pharmaceutical Research Why India is Gaining Popularity for Clinical Trials The Future of Kidney Transplants in India Usage of Conversational AI in the Health Insurance Sector Strategies for India to Reduce Its API Dependence on China Business Impact of USFDA Approvals on Indian Pharma Companies Innovative Strategies for Expanding Access to Life Saving Healthcare Solutions Badhal Village Crisis: How Rapid Diagnostics Could Have Saved Lives Why India is a Hotspot for Biotech Startups? Why Adapting Flexibility in IP Rights will Drive Generics Market Meeting the Challenges of High-Potency API (HPAPI) Production Impact of Human Factors Engineering on Medical Device Safety The Future of Pharma: Embracing Continuous Manufacturing The Role of Orphan Drugs in Treating Rare Diseases Emerging Technologies Shaping the Future of Drug Formulation Strategies for Optimizing Pharmaceutical Supply Chain Efficiency The Future of Medicine: Harnessing the Power of RNA-based Therapeutics AI in Medicine: Unmasking the Myths and Embracing the Transformative Reality Cycle Pharma Acquires Banner Life Sciences WHO's First-ever Global Summit on Traditional Medicine Starts in Gujarat The Importance of Data Integrity in Pharmaceutical Quality Control DCGI in Talks with Stakeholders to Develop a Standardised Web Platform to Assure Drug Quality and Patient Safety Glenmark Pharmaceuticals secures ANDA Nod for 0.03 per cent Tacrolimus Ointment Streamlining Laboratory Operations with a Modern LIMS Healthtech Start-up Suraksha QR Ropes In Actor Murali Sharma as its Brand Ambassador Unlocking the Potential of Pharmacogenomics: Enhancing Drug Safety and Efficacy The Impact of Pharmaceutical Testing on Drug Development India has Identified Three Health Priorities to Strengthen Global Health Infrastructure, says WHO National Health Authority launches 100 Microsites Project to Speed Up Digital Health Adoption India Should Partner with Australia to avail PBS for the Selection, Listing, and Pricing processes of exported drugs, says Sudarshan Jain Zydus Lifesciences India More than Doubles Profit Due to Increased Sales in the US India Triples Organ Donations over Past Decade says Union health minister Mansukh Mandaviya Advent Therapeutics Awarded $3 Million NIH Grant For Novel Neonatal Lung Therapy Three Pharma Marketing Strategies That Drive Sales Novartis Targets India's Rare Disease Market with 17 Clinical Programs UK Health Regulator approves GSK's Vaccine for the common respiratory virus RSV WHO Urges Increased Use Of Recommended Malaria-Fighting Tools Karnataka Budget Offered a Significant Boost to Health & Lifesciences Start-ups with Focus on Infrastructure & Innovation Three High Potential Moonshot Project Areas in Pharma CCI approves Bharat Biotech International-Eastman Exports deal How Biotech is Revolutionizing the Fight Against Cancer LifeCell and HaystackAnalytics ink strategic pact to scale-up TB whole genome sequencing pan-India Mankind Pharma IPO To Open On April 25 With A Price Fixed At Rs 1,026-1,080 Per Share US CDC Approves Second Omicron-Updated COVID Booster For Adults Three Trends that will Impact Pharmaceutical Industry in 2023 ModeX Therapeutics Commences Phase I EBV Vaccine Trial with Merck Designing Impactful Leadership and Talent Management Programs with Strategies for Success Novo Nordisk and Valo Health Partner to develop novel Treatments FOPE Calls for Extended Deadline for Schedule M Compliance Telix Pharma To Acquire ImaginAb to Boost Therapeutics and Innovation Roche Secures US FDA Approval for its Ultra-Sensitive ISH test Rappta Therapeutics and SpringWorks Partner on Molecular Glue Targeting PP2A Taro Pharma To Acquire entire stake in Antibe Therapeutics Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 Emcure Pharma Launches Largest R&D Centre in Ahmedabad Zydus Bags USFDA Nod for Phase II(b) Trial to Optimize Usnoflast Dosage US FDA Approves Amgen's Lumakras-Vectibix Combo for KRAS G12C-Mutated mCRC Glenmark Pharma Unveils generic anticoagulant injectable emulsion Strides Pharma Bags USFDA Nod for OTC Acetaminophen-Ibuprofen Combo Tablets US FDA Lifts Hold on Sanofi's Trial to Make Cialis Available Over-the-Counter Hoth Therapeutics Expands Intellectual Property with New Patents Jaguar Health Starts POC Trial of Crofelemer for Rare Pediatric Disease MVID Pharma and Healthcare Sector Eyes Union Budget 2025 for Innovation Boost How Innovative Drug Formulations are Enhancing Treatment Outcomes Apollo and Mayapada Healthcare Unite to Boost Indonesia's Healthcare Novo Nordisk Reports Positive Phase 1b/2a Results for Amycretin Govt to Extend Schedule M Compliance Deadline for Drug Manufacturers to Dec Lupin Secures US FDA Nod for Ipratropium Bromide Nasal Solution ANDA Granules Pharmaceuticals Secures USFDA Nod for Key Generic Drug Bajaj Healthcare Bags DCGI Nod to Manufacture Pimavanserin API & Formulation Union Budget 2025: Healthcare Gets 9.78% Boost, Allocation Nears 1 Lakh Crore Metropolis & Roche Launch Self-Sampling HPV Test for Cervical Cancer Sigachi Industries Invests $1M in Hyderabad R&D Hub for API Innovation Pharma Testing Market Surges with Rising Demand for Biologics ISTH Releases Clinical Practice Guideline For Haemophilia Treatment Sanofi and Biovac Lead Polio Vaccine Manufacturing Capabilities Sun Pharma and Takeda Ink Pact To Market Gastrointestinal Drug Takeda and Ascentage Pharma Ink Option Agreement For Olverembatinib Enhancing Compliance through Effective Pharmaceutical Regulatory Affairs Strategies India poised to become a Global Hub for Clinical Trials: Exec SCHOTT Pharma Unveils Next-Gen Polymer Syringes for Enhanced Safety GSK's Jemperli Gains EU Nod for First-Line Treatment of Endometrial Cancer Union Health Secretary Urges Stronger Drug Regulations for Quality Control Telangana Govt Inks Landmark Deals to Propel Life Sciences and Job Growth R&D in Indian Pharma: Breakthroughs and Innovations in 2024 Dr. Reddy's Partners with Shanghai Henlius to Develop Cancer Drug Uniphar Expands Global Footprint with Three New Facilities 74th Indian Pharmaceutical Congress 2025 Opens Registrations AGC Pharma Expands HPAPI Capabilities in Barcelona to Meet Growing Demand The Future of Genomic Sequencing: Trends That Will Define the Next Decade Lexaria Bioscience Ethics Review Board Nod to Commence New GLP-1 Study Amitabh Kant Urges India to Focus on Innovation at BioAsia 2025 Government Enhances Research & Integration Initiatives in Unani Medicine Blind & Deaf individuals face Major Barriers to access Medicines: Report C-CAMP and PariSante Campus launched Indo-French Life Sciences Hub Jaguar Health Begins Pediatric Trial for Crofelemer in Short Bowel Syndrome Algiax Pharma Reports Promising Phase 2a Results for AP-325 Govt Bans 34 Antimicrobials for Use in Animals Pharmaceutical Procurement Strategies: How to Optimize Costs Personalized Medicine: Get Tailored Treatment Plans for You Now How to Bridge the Healthcare Gap in Emerging Markets with MedTech The Evolution of In-Vitro Diagnostics: Trends and Future Prospects Needle-Free Injection System: A Game Changer in Less Pain Vaccination How Global Capability Centers are Shaping the Future of Biometrics Building a Successful Pharma Brand in India: The Role of Scientific Communication Unlocking India's Innovation Potential in Pharma The Future of Green Chemistry in API Production Top 10 Pharmaceutical Recruitment Consultants - 2024 | Pharma Outlook Blockchain for Secure Pharmaceutical Supply Chains - 2025 & Beyond Mass Spectrometry in Biomarker Discovery for Early Disease Detection Iconovo and Lonza Team up to Advance Intranasal Biologic with ICOone Nasal Fetal Imaging to Cardiac Diagnosis: The Expanding Role of Ultrasound Balancing Innovation and Affordability in Medical Solutions for India Changing Landscape for LTBI and Syndromic Testing Methodologies How Advanced Training Methods can Enhance Patient Care Balancing Cost Efficiency and Compliance in Pharmaceutical Manufacturing LUB Urges Govt to Scrap Mandatory Lab Testing for Cough Syrup Exports Role of Optical Imaging in Early Cancer Detection and Treatment Hoth Therapeutics Unveils Promising Data for KIT-Targeting Therapy Pharmexcil Engages ASEAN Nations to Boost Pharma Trade Ties Fortis Partners with Teleflex for South Asia UroLift Training Anti-Infectives: How New Research is Shaping Infection Control Building Bridges for Sustainable Growth through Strategic Alliances in Ethical Pharmaceuticals Quality as the Cornerstone of Lab Solutions FDA Approves Roch's NSCLC Diagnostic Linked to Emrelis How Early Detection is Transforming Cancer Treatment in India Ensuring Data Privacy in Pharma World Enhancing Clinical Trial Supply Chain Resilience to Address Global Disruptions in India Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings How Organic Synthesis is Accelerating Drug Discovery in Pharma Strategic finance for pharmaceutical innovation and stability Top 10 Teleradiology Service Providers - 2024 | Pharma Outlook Importance of Investing in R&D and Quality for Competitive Advantage in Eye Care Top 10 In Vitro Diagnostics Companies - 2024 | Pharma Outlook Phytopharmaceuticals: Driving Global Herbal Medicine Innovation Gender Gap in Healthcare: Why Women's Health Needs More Research Impact of Modern Technology on the Indian Life Sciences Sector Why Global Pharma Expects CDMOs to Be Ready for Joint Inspections The Role of Customizable Stent Grafts for Treating Complex Anatomies Nutraceuticals vs Pharmaceuticals: Complementary or Alternative in Chronic Disease Management? Top 10 Pharma CDMO Companies In India – 2023 | Pharma Outlook Leaping Towards Global Compliance with Revised Schedule M Meril Concludes TechVentory, Boosts AI-Driven Healthcare Supply Chains 10 Pharma Sector Revolutions in India Standardizing Medicine Labeling and Embracing Digital Transformation Creating a patient-centric healthcare ecosystem for all Biomanufacturing of Enzymes: A Sustainable Approach to Industrial Biotechnology Integrating CSR into HR Practices to Enhance Brand Reputation in Pharma Merck Launches Phase 3 Trial for Promising Dengue Vaccine V181 Breakthrough: Eye-Opening Healthcare Strategies Doctors Swear By on Doctor's Day 2025 Bristol Myers Squibb Reports Strong Phase 3 Results for Deucravacitinib trail Alcon Launches Innovative Daily Lenses Designed for Long-lasting Comfort Apisolex Excipient by Lubrizol Backs Phase I Drug Success FDA Approves Enflonsia to Prevent RSV in Infants with One Dose Biosimilars in India 2025 Market Trends, Growth Forecast & Opportunities How Regulations Are Shaping India's Medical Device Landscape Bharat Biotech Partners with GSK for Shigella Vaccine Development Eli Lilly Obesity Drug Shows 11.5% Weight Loss in 12 Weeks Laborate Pharmaceuticals: Illuminating Pathways Of Quality, Affordability Innovation In Healthcare Sun Pharma Bags CDSCO Approval to Produce Fexuprazan Hydrochloride Tablets The Fusion of Biology, Medicine, Health, and AI Glenmark Gets DCGI Nod to Launch Oncology Drug BRUKINSA in India Kyndryl Partners with Dr Reddys to Automate Global IT Operations How Robotic Assisted Surgery Is Redefining Precision in Kidney Transplants Top 10 Women Disruptors in Asia Pharmaceutical Industry

Editor's Guest

Related Articles


© 2025 India Pharma Outlook. All Rights Reserved.